Trailhead Biosystems Expands iPSC-Derived Cell Portfolio With TrailBio Endothelial Cells
Trailhead Biosystems has launched a functionally validated, highly pure iPSC-derived endothelial cell product designed to give researchers a scalable, reproducible human vascular model for angiogenesis, inflammation, drug screening and toxicity studies.
Key Points
- Trailhead Biosystems has launched TrailBio® Endothelial Cells, an induced pluripotent stem cell (iPSC)-derived endothelial cell product for vascular research.
- The company says the cells are functionally validated, more than 90% pure, and designed to provide a more reproducible alternative to donor-derived primary endothelial cells.
- TrailBio® Endothelial Cells are intended for angiogenesis, inflammation, drug screening, and toxicity studies.
Product Launch
Ohio-Based Trailhead Biosystems has launched TrailBio® Endothelial Cells, an induced pluripotent stem cell (iPSC)-derived model for research on the human vascular endothelium. The cells are intended for angiogenesis, inflammation, drug screening, and toxicity testing in discovery and translational research.
The product was developed using the company’s automated High-Dimensional Design-of-Experiments (HD-DoE®) platform.
Get Regen Report in your inbox
Weekly updates on regenerative medicine news, trials, and regulatory moves.
HD-DoE combines mathematical modeling, machine learning, and robotic automation to map, analyze, and optimize the complex environmental conditions required to differentiate induced pluripotent stem cells (iPSCs) into specific cell types for research and drug discovery.
Cell Characteristics and Research Use
According to the company, TrailBio® Endothelial Cells express key endothelial markers including CD31, CD144, and von Willebrand Factor, with greater than 90% purity. The cells were also functionally validated in several in vitro assays.
- Angiogenic tube formation
- VEGF-stimulated migration and invasion
- Inflammatory activation in response to TNF-α
- Acetylated LDL uptake
Trailhead says each cryopreserved vial contains 1 million viable endothelial cells. The cells can be used immediately after thawing or expanded in culture for at least three passages without loss of phenotype or function.
You can download the product data sheet here.
“These endothelial cells deliver a well-balanced combination of purity, functional performance and scalability,” said Angelica Gomes Ueltschy, Scientific Director at Trailhead Biosystems. “Their validated angiogenic and inflammatory responses make them well-suited for studying vascular biology and evaluating therapeutic candidates in controlled, reproducible assays.”
Additional product information is available on Trailhead Biosystems’ website.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
